Bariatric Surgery Outperforms GLP-1 Drugs for Significant Weight Loss, New Study Reveals
If you’re among the millions considering weight loss interventions, a new reality check is in order. A recent study reveals that bariatric surgery delivers dramatically more substantial and lasting weight loss than popular injectable medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro). Researchers found that, after two years, surgical patients lost five times more weight than those relying on GLP-1 receptor agonists – a gap that challenges the narrative surrounding these increasingly common drugs.
The Weight Loss Divide: Surgery vs. Medication
The research, presented at the American Society for Metabolic and Bariatric Surgery (ASMBS) 2025 Annual Scientific Meeting, analyzed data from over 51,000 patients treated at NYU Langone Health and NYC Health + Hospitals between 2018 and 2024. Patients undergoing sleeve gastrectomy or Roux-en-Y gastric bypass experienced an average weight loss of 58 pounds, equating to 24% of their total body weight. In stark contrast, those prescribed GLP-1 medications for at least six months lost just 12 pounds (4.7% total weight loss), and even a full year of continuous therapy yielded only a 7% reduction.
This isn’t simply a matter of degree; it’s a significant difference with implications for long-term health and treatment strategies. The study underscores a critical disconnect between the promising results seen in controlled clinical trials and the outcomes observed in real-world clinical practice.
Why the Discrepancy? Real-World Challenges with GLP-1s
Lead author Dr. Avery Brown of NYU Langone Health points to several factors contributing to the lower efficacy of GLP-1s outside of clinical trials. “Clinical trials show weight loss between 15% to 21% for GLP-1s, but this study suggests that weight loss in the real world is considerably lower even for patients who have active prescriptions for an entire year,” she explains. “We know as many as 70% of patients may discontinue treatment within one year.”
Adherence is a major hurdle. Side effects, the financial burden of ongoing prescriptions, and the demands of lifestyle changes all contribute to treatment discontinuation. As a result, many patients may not experience the full benefits advertised, leading to frustration and potentially a return to previous weight levels. This highlights the importance of realistic expectations and a comprehensive approach to weight management.
Bariatric Surgery: A Durable Solution, Still Underutilized
While both approaches result in weight loss, the study reinforces that **bariatric surgery** offers a more effective and durable solution for significant weight reduction. However, despite its proven benefits, bariatric surgery remains significantly underutilized. In 2023, only about 1% of individuals meeting the BMI eligibility criteria underwent a metabolic and bariatric procedure, with just over 270,000 surgeries performed nationwide, according to the ASMBS.
“Those who get insufficient weight loss with GLP-1s or have challenges complying with treatment due to side effects or costs, should consider bariatric surgery as an option or even in combination,” states ASMBS President Dr. Ann M. Rogers. This suggests a potential for a more integrated approach, where GLP-1s might be used as a bridge to surgery or as an adjunct therapy post-surgery to maximize long-term success.
Looking Ahead: Optimizing GLP-1 Outcomes and Personalized Treatment
Researchers are already focusing on ways to improve the effectiveness of GLP-1 medications. Senior author Dr. Karan Chhabra emphasizes the need for future studies to identify strategies for optimizing GLP-1 outcomes, determining which patients are best suited for surgery versus medication, and understanding the impact of out-of-pocket costs on treatment success.
The increasing prevalence of obesity – affecting 40.3% of U.S. adults, with 9.4% experiencing severe obesity according to the CDC – underscores the urgency of finding effective solutions. Obesity isn’t just a cosmetic concern; it’s a major risk factor for cardiovascular disease, stroke, type 2 diabetes, and certain cancers.
The future of weight loss treatment likely lies in a personalized approach, combining medical interventions with lifestyle modifications and addressing the individual needs and challenges of each patient. As research continues to evolve, a more nuanced understanding of the benefits and limitations of both bariatric surgery and GLP-1 medications will be crucial for empowering patients to make informed decisions about their health.
What role do you see for emerging technologies and personalized medicine in the future of obesity treatment? Share your thoughts in the comments below!
